Literature DB >> 33534604

Group 2 Innate Lymphoid Cells: Team Players in Regulating Asthma.

Noe Rodriguez-Rodriguez1, Mayuri Gogoi1, Andrew N J McKenzie1.   

Abstract

Type 2 immunity helps protect the host from infection, but it also plays key roles in tissue homeostasis, metabolism, and repair. Unfortunately, inappropriate type 2 immune reactions may lead to allergy and asthma. Group 2 innate lymphoid cells (ILC2s) in the lungs respond rapidly to local environmental cues, such as the release of epithelium-derived type 2 initiator cytokines/alarmins, producing type 2 effector cytokines such as IL-4, IL-5, and IL-13 in response to tissue damage and infection. ILC2s are associated with the severity of allergic asthma, and experimental models of lung inflammation have shown how they act as playmakers, receiving signals variously from stromal and immune cells as well as the nervous system and then distributing cytokine cues to elicit type 2 immune effector functions and potentiate CD4+ T helper cell activation, both of which characterize the pathology of allergic asthma. Recent breakthroughs identifying stromal- and neuronal-derived microenvironmental cues that regulate ILC2s, along with studies recognizing the potential plasticity of ILC2s, have improved our understanding of the immunoregulation of asthma and opened new avenues for drug discovery.

Entities:  

Keywords:  alarmin; allergy; asthma; innate lymphoid cells; neuroimmunity; type 2 immunity

Mesh:

Substances:

Year:  2021        PMID: 33534604     DOI: 10.1146/annurev-immunol-110119-091711

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  13 in total

Review 1.  Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.

Authors:  Sharon Grisaru-Tal; Marc E Rothenberg; Ariel Munitz
Journal:  Nat Immunol       Date:  2022-08-24       Impact factor: 31.250

2.  Rapamycin Dampens Inflammatory Properties of Bone Marrow ILC2s in IL-33-Induced Eosinophilic Airway Inflammation.

Authors:  Emma Boberg; Julie Weidner; Carina Malmhäll; Jenny Calvén; Carmen Corciulo; Madeleine Rådinger
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 3.  Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13.

Authors:  Corrado Pelaia; Giulia Pelaia; Claudia Crimi; Angelantonio Maglio; Giuseppe Armentaro; Cecilia Calabrese; Angela Sciacqua; Luca Gallelli; Alessandro Vatrella
Journal:  Vaccines (Basel)       Date:  2022-06-19

4.  Small Proline-Rich Protein 3 Regulates IL-33/ILC2 Axis to Promote Allergic Airway Inflammation.

Authors:  Guiping Zhu; Hui Cai; Ling Ye; Yuqing Mo; Mengchan Zhu; Yingying Zeng; Xixi Song; Chengyu Yang; Xin Gao; Jian Wang; Meiling Jin
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

5.  Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis.

Authors:  Corrado Pelaia; Nicola Lombardo; Maria Teresa Busceti; Giovanna Piazzetta; Claudia Crimi; Cecilia Calabrese; Alessandro Vatrella; Girolamo Pelaia
Journal:  J Asthma Allergy       Date:  2021-09-24

Review 6.  The discovery of group 2 innate lymphoid cells has changed the concept of type 2 immune diseases.

Authors:  Tetsuro Kobayashi; Yasutaka Motomura; Kazuyo Moro
Journal:  Int Immunol       Date:  2021-11-25       Impact factor: 4.823

Review 7.  The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations.

Authors:  McKella Sylvester; Aran Son; Daniella M Schwartz
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 8.  Heterogeneity of type 2 innate lymphoid cells.

Authors:  Hergen Spits; Jenny Mjösberg
Journal:  Nat Rev Immunol       Date:  2022-03-30       Impact factor: 53.106

Review 9.  Respiratory Viral and Bacterial Factors That Influence Early Childhood Asthma.

Authors:  Nontobeko Mthembu; Paul Ikwegbue; Frank Brombacher; Sabelo Hadebe
Journal:  Front Allergy       Date:  2021-07-22

10.  Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy.

Authors:  Corrado Pelaia; Claudia Crimi; Santi Nolasco; Giovanna Elisiana Carpagnano; Raffaele Brancaccio; Enrico Buonamico; Raffaele Campisi; Claudia Gagliani; Vincenzo Patella; Girolamo Pelaia; Giuseppe Valenti; Nunzio Crimi
Journal:  Biomedicines       Date:  2021-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.